

1 Distal Ventricular Pacing for Drug-Refractory Mid-Cavity Obstructive Hypertrophic
2 Cardiomyopathy: A Randomized, Placebo-Controlled Trial of Personalized Pacing.

3

4 James W Malcolmson^{1,2}, Rebecca K Hughes^{1,3}, Tim Husselbury¹, Kamran Khan²,
5 Annastazia E Learoyd², Martin Lees¹, Eleanor C Wicks^{3,4}, Jamie Smith⁵, Alexander
6 Simms⁶, James Moon^{1,3}, Luis Lopes^{1,3}, Constantinos O'Mahony^{1,3}, Neha Sekhri¹,
7 Perry Elliott^{1,3}, Steffen E. Petersen^{1,2,7}, Mehul Dhinoja¹, Saidi A Mohiddin^{1,2}.

8

- 9 1. Barts Heart Center, St Bartholomew's Hospital, Barts Health NHS Trust, West
10 Smithfield, EC1A 7BE, London, UK
- 11 2. William Harvey Research Institute, NIHR Barts Biomedical Research Center,
12 Queen Mary University London, Charterhouse Square, London, EC1M 6BQ,
13 London, UK
- 14 3. Institute of Cardiovascular Science, University College London, WC1E 6BT, UK
- 15 4. Inherited Cardiovascular Diseases Unit, John Radcliffe Hospital, Oxford, OX3
16 9DU, UK
- 17 5. Raigmore Hospital, NHS Highland, Old Perth Rd, Inverness IV2 3UJ, UK
- 18 6. Yorkshire Heart Center, Leeds Teaching Hospital NHS Trust, Leeds, LS1 3EX,
19 UK
- 20 7. Health Data Research UK, Gibbs Building, 215 Euston Road, NW1 2BE, London,
21 UK

22

23 **Short title:** Pacing for mid-cavity hypertrophic cardiomyopathy.

24 **Corresponding author:**

25 Professor Saidi. A. Mohiddin

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 saidi.mohiddin@nhs.net

27 Department of Inherited Cardiovascular

28 Disease Unit SBH

29 St Bartholomew's Hospital

30 West Smithfield

31 London EC1A 7BE

32

33 **Word count** 3586 (exclusive of title, abstract, references, tables, and figure legends)

34

35 **Abstract**

36 **Background:** Patients with refractory symptomatic left ventricular (LV) mid-cavity
37 obstructive (LVMCO) hypertrophic cardiomyopathy (HCM) have few therapeutic
38 options. Right ventricular (RV) pacing is associated with modest hemodynamic and
39 symptomatic improvement, and LV pacing pilot data suggest therapeutic potential.
40 We hypothesized site-specific-pacing would reduce LVMCO gradients and improve
41 symptoms.

42 **Methods:** Patients with symptomatic-drug-refractory LVMCO were recruited for a
43 randomized blinded trial of personalized prescription of pacing (PPoP). Multiple LV
44 and apical RV pacing sites were assessed during invasive hemodynamic study of
45 multisite pacing. Patient-specific pacing-site and atrioventricular (AV) delays,
46 defining PPoP, were selected on basis of LVMCO gradient reduction and acceptable
47 pacing parameters. Patients were randomized to 6-months of active PPoP or back-
48 up pacing in a cross-over design. The primary outcome examined invasive gradient
49 change with best-site pacing. Secondary outcomes assessed quality of life and
50 exercise following randomization to PPoP.

51 **Results:** A total of 17 patients were recruited; 16 of whom met primary endpoints.
52 Baseline NYHA was 3 ± 0.6 despite optimal medical therapy. Hemodynamic effects
53 were assessed during pacing at the RV apex and at a mean of 8 LV sites. The
54 gradients in all 16 patients fell with pacing, with maximum gradient reduction
55 achieved via LV pacing in 14 (88%) patients and RV apex in 2. The mean baseline
56 gradient of 80 ± 29 mmHg, fell to 31 ± 21 mmHg with best-site pacing, a 60% reduction
57 ($p<0.0001$). One cardiac vein perforation occurred in one case, and 15 subjects
58 entered cross-over; 2 withdrawals occurred during cross-over. Of the 13 completing
59 cross-over, 9 (69%) chose active pacing in PPoP configuration as preferred setting.

60 PPOp was associated with improved 6-minute walking test performance (328.5±99.9
61 vs 285.8±105.5 meters, p=0.018); other outcome measures also indicated benefit
62 with PPOp.

63 **Conclusions:** In a randomized placebo-controlled trial, LV pacing reduces
64 obstruction and improves exercise performance in severely symptomatic LVMCO
65 patients.

66 **Registration:** NCT03450252.

67

68 **Keywords:**

69 Hypertrophic cardiomyopathy, pacemaker, mid-cavity obstruction

70

71

72

73 **Non-standard Abbreviations and Acronyms**

74	AE	Adverse Event
75	ASA	Alcohol septal ablation
76	AF	Atrial fibrillation
77	AV	Atrioventricular
78	CPET	Cardiopulmonary exercise test
79	CI	Confidence intervals
80	CMR	Cardiac magnetic resonance
81	CVCTU	Cardiovascular Clinical Trials Unit
82	ECG	Electrocardiogram
83	eGFR	Estimated glomerular filtration rate
84	ESC	European Society of Cardiology
85	GA	General anesthesia
86	HCM	Hypertrophic cardiomyopathy
87	HTN	Hypertension
88	ICD	Implantable cardioverter defibrillator
89	IQR	Interquartile range
90	ISRCTN	International Standard Randomized Controlled Trials Number
91	KCCQ	Kansas City Cardiomyopathy Questionnaire
92	LA	Left atrial
93	LGE	Late gadolinium enhancement

94	LV	Left ventricle
95	LVAA	Left ventricular apical aneurysm
96	LVEF	Left ventricular ejection fraction
97	LVMCO	Left ventricular mid cavity obstruction
98	LVOTO	Left ventricular outflow tract obstruction
99	LVWT	Left ventricular wall thickness
100	MCV	Middle cardiac vein
101	MI	Myocardial infarction
102	NIHR	National Institute of Health and Care Research
103	NSVT	Non-sustained ventricular tachycardia
104	NT-proBNP	N-terminal pro B-type natriuretic peptide
105	NYHA	New York Heart Association
106	PPM	Permanent pacemaker
107	PPoP	Personalized prescription of pacing
108	RV	Right ventricular
109	SCD	Sudden cardiac death risk
110	SD	Standard deviation
111	SF-36	Short form 36 questionnaire
112	6MWT	6-minute walk test
113		

114 **Clinical Perspective:**

115 **What is Known?**

- 116 • Patients with refractory, symptomatic LVMCO present a significant challenge
117 for clinical management, with very few treatment options.
- 118 • Data on the use of right ventricular (RV) pacing in patients with refractory,
119 symptomatic LVMCO indicate suboptimal therapeutic responses whilst pilot
120 data indicate a potential therapeutic role for LV pacing.


121 **What the Study Adds?**

- 122 • Personalized prescription of pacing (PPoP) therapy guided by invasive
123 hemodynamics significantly reduced LVMCO gradients and improved
124 exercise performance in the first randomized, placebo-controlled trial in
125 symptomatic LVMCO.
- 126 • This study provides the basis for a multicenter trial of PPoP for LVMCO and
127 for the use of site-specific pacing in managing other forms of HCM.

128

129 **Graphical Abstract:**

130



131
132

133 **1. Introduction**

134 Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease,
135 affecting around 1 in 500 people.¹ HCM is characterized by abnormal myocardial
136 thickening and hypercontractility, with obstruction to blood flow within the left
137 ventricle (LV) frequently seen at the level of the outflow tract, associated with
138 morbidity and adverse prognosis.^{2, 3} LV mid-cavity obstruction (LVMCO) is a less
139 commonly recognized phenotypic form of HCM in which obstruction during LV
140 ejection occurs due to partial or complete obliteration and division of the LV cavity
141 into two distinct areas (basal and apical). Here, hyperdynamic muscular contraction
142 forms a constricting muscular neck at the point of cavity division.^{4 5} High intracavity
143 pressure gradients form across the point of obstruction, often associated with the
144 development of discrete LV apical aneurysms (LVAA),⁶ a risk factor for adverse
145 events.⁷

146 Patients with LVMCO are often symptomatic,⁸ and first-line pharmacologic therapies
147 (including betablockers, calcium channel antagonists, and disopyramide) aim to
148 reduce LV inotropy and/or increase filling time. Those with symptoms refractory to
149 medical therapy have severely limited therapeutic options. Studies have indicated
150 that pacing may reduce obstructive gradients and improve symptoms in LVMCO.^{9, 10}
151 Notably, as we and others have shown,^{4, 11, 12} Doppler derived assessments often
152 severely underestimate LVMCO gradient magnitude and invasive methods are
153 needed for accurate measurement.

154 Our group has pioneered the use of invasive hemodynamic assessments made
155 during a multi-site pacing study to determine optimal pacing configurations. Initial
156 data obtained in severely symptomatic LVMCO patients with conventional indications

157 for device therapy demonstrated that this personalized prescription of pacing (PPoP)
158 approach reduced LVMCO gradients, and was associated with symptomatic
159 improvement in an unrandomized cohort of 16 patients.¹³ These observational data
160 informed the design of this randomized, placebo controlled cross-over trial of PPoP.
161 Here, we hypothesized that PPoP as guided by invasive hemodynamic
162 measurements of arterial and LV pressures to accurately define obstructive
163 gradients⁴ would reliably reduce LVMCO gradient severity (primary aim) and improve
164 functional status (secondary aims).

165

166 **2. Methods**

167 **Study design and participants**

168 This was a single-center, prospective study of distal ventricular pacing for gradient
169 reduction and symptomatic relief in HCM patients with isolated LVMCO. Ethical
170 approval was granted by the National Research Ethics Service, City Road and
171 Hampstead, London (Reference: 17/LO/1725). The trial was performed in agreement
172 with the Declaration of Helsinki and registered with the following public registries:
173 <http://clinicaltrials.gov> (NCT03450252) and International Standard Randomized
174 Controlled Trials Number (ISRCTN): ISRCTN82621856. The study was funded by
175 the National Institute for Health and Care Research (NIHR) in the United Kingdom.

176 Only LVMCO patients with severe drug-refractory symptoms were included. Eligible
177 HCM patients were ≥ 18 years with LVMCO gradient ≥ 30 mmHg demonstrated
178 initially by echocardiography, and confirmed by cardiac catheterization at rest or with
179 isoprenaline provocation, referred for pacemaker (PPM) +/- implantable cardioverter
180 defibrillator (ICD) implantation for either primary prevention of sudden cardiac death
181 or other indications such as heart block or obstructive physiology; patients were
182 taking maximum tolerated doses of beta blockers or verapamil +/- disopyramide.

183 Exclusion criteria included multi-level obstruction (i.e. across the mid-cavity and
184 outflow tract if the latter was determined to be the dominant lesion); moderate or
185 severe primary valvular disease; untreated symptomatic coronary disease; atrial
186 fibrillation at the time of device implantation; pregnancy; eGFR < 20 mL/min; and
187 patients unable to provide informed consent. Inclusion and exclusion criteria are fully
188 listed in Table 1.

189 **Study design overview**

190 Baseline evaluation of symptom and performance (secondary outcome measures)
191 included NYHA class, Short Form-36 (SF-36) questionnaire scores, Kansas City
192 Cardiomyopathy Questionnaire (KCCQ) scores, 6-minute walk test (6MWT)
193 distance, cardiopulmonary exercise testing (CPET) with stress echocardiography,
194 and serum concentration of N-terminal pro B-type natriuretic peptide (NT-proBNP).
195 Subjects then underwent an invasive hemodynamic assessment of multi-site pacing
196 study to guide LV and RV lead positioning and device implantation. Primary outcome
197 data were collected during the hemodynamic pacing study and comprised of the
198 acute invasively determined changes in LVMCO gradient at the optimal pacing site
199 when compared to sinus rhythm. Quadripolar LV lead position was determined
200 according to a pragmatic synthesis of pacing-site-specific hemodynamic data and
201 appropriate pacing parameters at that site (including thresholds and
202 diaphragmatic/phrenic capture).
203 On the day following device implant, participants were randomized to either active or
204 back up pacing for the first phase of follow-up (6 months), before crossover to the
205 alternate setting for the second 6-month period. Secondary outcome data were again
206 assessed at the end of each follow-up phase. Participant and Principal Investigator
207 were blinded to pacing status, and the subject's stated preference of either 1st or 2nd
208 crossover phase was a prespecified secondary outcome measure.

209 **Hemodynamic pacing study**

210 We have previously described the technique for hemodynamic pacing procedure in
211 detail.¹³ Briefly, all hemodynamic pacing studies and device implants were performed
212 in a single procedure under general anesthesia (GA). Arterial access was achieved
213 via the right femoral artery using the Seldinger technique (operator 1) with central

214 venous access similarly achieved via the left sub-clavian or cephalic veins (operator
215 2).

216 Operator 2 advanced the right atrial and RV leads to the heart via the superior vena
217 cava, where they were implanted using standard techniques for active leads
218 (manufacturer dependent). The coronary sinus was intubated using a LV lead
219 delivery guiding catheter and the coronary venous anatomy defined by simultaneous
220 balloon occlusion coronary sinus venography and LV angiography. The coronary
221 vein of interest was intubated with a deflectable quadripolar catheter.

222 During the hemodynamic pacing protocol, pressures were transduced
223 simultaneously from the LV apex using a specially manufactured end-hole pigtail
224 catheter (Cordis™) and femoral artery via a 7French side arm sheath. Baseline
225 peak-to-peak obstructive gradients were calculated in sinus rhythm; if no resting
226 obstructive gradient was present under GA conditions, steady state isoprenaline
227 infusion was used in provocation: this began at 1 microgram/minute and, if required,
228 was gradually up-titrated to a maximum of 4 micrograms/minute.^{14 15}

229 To select the optimal sensed AV delay, an initial AV delay (60 ms) was lengthened
230 until evidence of QRS fusion was seen on the surface electrocardiogram (ECG)
231 and/or when acute gradient reduction was lost. For each of several pacing
232 configurations (quadripolar LV catheter, RV apex; in unipolar and bi-polar) the best
233 ventricular pacing location (primary outcome) was identified solely according to the
234 greatest acute reduction in obstructive gradient. Each pacing site was systematically
235 tested by turning pacing 'on' for a period of 30 seconds to allow stabilization of
236 hemodynamics, before averaging invasively defined LVMCO gradients over 3
237 consecutive cardiac cycles. When pacing was turned 'off' at an individual site,

238 another 30 second period was initiated to allow for stabilization of intracardiac
239 hemodynamics. When selecting the pragmatic pacing site for PPop, other pacing
240 related factors (including capture threshold, r-wave sensitivity, diaphragmatic
241 capture, change in surface ECG QRS morphology, lead stability) and hemodynamic
242 responses (the maintenance or improvement in systolic arterial pressure) were also
243 considered by the Principal Investigators (operators 1 and 2).

244 The assessment of obstructive gradients during various pacing configurations was
245 obtained sequentially, beginning with single site pacing from the RV apex, followed
246 by multi-site LV pacing from a quadripolar lead in the middle cardiac or other cardiac
247 vein (venous anatomy dependent). Hemodynamic consequences of multi-site LV
248 pacing were assessed sequentially from distal to proximal poles 1-4. Repositioning
249 of the quadripolar lead in the same or alternative cardiac veins was performed when
250 sub-optimal hemodynamic results were obtained, and/or when pacing parameters or
251 lead stability were unsatisfactory. After final pacing parameters were identified,
252 careful pull-back of the pigtail catheter confirmed site and magnitude of resting and
253 pacing obstruction within the LV.

254 **Statistical analysis**

255 **Sample size calculation**

256 Effect size was calculated using our retrospective LVMCO pacing data,¹³ where
257 mean acute reduction in mid-cavity gradient with distal ventricular pacing was 60 ± 26
258 mmHg. A conventional significant obstructive gradient is 30 mmHg,¹⁶ and using a
259 conservative approach, we aimed to be able to detect a reduction of 25 mmHg. With
260 the two-sided alpha level set at 0.05 a priori, and a power of 90%, the calculated
261 sample size using a paired sample t-test was 15.

262 **Randomization**

263 Patients were randomized to either active or back-up pacing one day after device
264 implantation using a 1:1 ratio. A master randomization list was generated in an
265 appropriate statistical package (STATA, using the ralloc command) to active or back-
266 up pacing with block size varied randomly.

267 **Analysis of primary endpoint**

268 All patients completing the initial hemodynamic pacing study were eligible for primary
269 analysis. Comparison of the gradients during ventricular pacing and sinus rhythm
270 was made using a paired t-test. The effect size is presented as the mean difference
271 (optimum pacing minus sinus rhythm gradients) and 95% confidence interval. In
272 addition, the mean values and standard deviations (SD) for gradients during both
273 sinus rhythm and pacing are presented.

274 **Analysis of secondary endpoints**

275 The proportions completing each assessment and the proportion withdrawing were
276 used to assess feasibility of the study. Secondary outcomes were compared
277 between baseline and pacing settings using repeated measures analyses (ANOVA
278 or Friedman tests depending on normality of distribution using the D'Agostino &
279 Pearson test) with multiple comparisons tests (Tukey's or Dunn's depending on
280 normality) providing a direct comparison between active and back-up pacing
281 settings. Changes between pacing settings during randomized follow-up in each
282 variable were calculated as the value for active pacing minus the value for back-up
283 pacing for each patient. Data are presented as mean \pm SD or median and interquartile
284 range (IQR) as appropriate.

285 Data was examined for the presence of carry-over period effects. No carry-over
286 effect was found. There was minor evidence of a period effect influencing the KCCQ
287 results which was not deemed to substantially affect the results presented.
288 All analyses were performed in RTM version 2022.27.1, and figures created in
289 Graphpad PrismTM version 9.5.1.

290

291 **Study Overview and Data Monitoring**

292 Study overview was provided by the Cardiovascular Clinical Trials Unit (CVCTU) at
293 the William Harvey Research Institute, London. Trial safety data was reviewed
294 routinely by an independent Data Safety Monitoring Committee, and oversight
295 provided by independent Trial Steering Committee. All trial data was held in a secure
296 database (REDCAPTM), source data verification undertaken by CVCTU monitors,
297 and statistical analyses performed by CVCTU statistician.

298

299 **3. Results**

300 **General characteristics of population**

301 Between February 2018 and March 2022, 17 patients were recruited to the trial. 29
302 patients were pre-screened for eligibility during work-up for potential invasive therapy
303 for LVMCO and refractory symptoms in a specialist heart muscle / electrophysiology
304 clinic after referral from their primary clinician (Figure 1). Of these 29, 12 patients
305 were excluded after not meeting symptomatic inclusion criteria (n=11), and 1 clinical
306 event prior to trial recruitment taking place (symptomatic ventricular arrhythmia and
307 urgent dual chamber ICD implant).

308 **Baseline characteristics**

309 The study population consisted of 17 patients on maximal tolerated medical therapy
310 with LVMCO. Of these, 53% were female, and mean age at recruitment 55.9 ± 10.3
311 years (Table 2). One patient was withdrawn before the implant procedure due to
312 comorbidities. Of the 16 who underwent hemodynamic pacing study and had devices
313 implanted, 15 (94%) patients received an ICD and one patient received a pacemaker
314 device. At baseline assessment, 17 (100%) patients reported exertional dyspnea, 15
315 (88%) reported exertional chest pain, 16 (94%) reported palpitations, and 14 (82%)
316 reported presyncope. Seven patients (41%) reported prior unexplained complete
317 loss of consciousness.

318 **Primary end point: acute change in invasive gradient**

319 Primary end point assessment was completed in 16 patients. Hemodynamic effects
320 of distal ventricular pacing were assessed from the RV apex in all patients, and
321 additionally in a mean of 8 LV sites (range 4-16). LV pacing was achieved via the
322 middle cardiac vein in 10, and another cardiac vein in four. All LVMCO gradients fell
323 with pacing.

324 The mean LVMCO gradient at baseline was 80 ± 29 mmHg (range 40-139), falling to
325 31 ± 21 mmHg (range 0-80) when paced from the optimal ventricular site. This
326 represents a mean fall in LVMCO gradient of -49 mmHg (95% CI -62 to -36 mmHg,
327 $p < 0.0001$) (Figure 2). Alternatively, this can be expressed as a mean 60% reduction
328 (range 14-100%). The greatest reductions in LVMCO were from a pacing site in the
329 LV in 14 (87.5%) patients, and from the RV apex in 2.

330 **Secondary endpoints**

331 Pre-implant assessment and both pacing settings during follow-up were completed
332 by 13 patients (with the order of active or back-up pacing randomized) who were
333 eligible for comparison of secondary endpoints between the three time points.
334 Reasons for drop-out are discussed under adverse events below.

335 **Participant choice of favored pacing setting:** At the end of the final study visit,
336 whilst still masked to treatment allocation, subjects were asked in which phase, if
337 any, they felt better. Nine of 13 (69%) subjects chose the active pacing phase as
338 their preferred setting. The remaining 4 (31%) patients reported no difference in
339 symptoms between the two phases.

340 **NYHA class:** Subjects self-reported NYHA class on 'good' and 'bad' days (Figure 3
341 panels A and B). Median NYHA class on a good day was 3 pre implant, 2 in the
342 active pacing arm, and 3 in the back-up pacing arm (IQRs all 2 to 3, $p = 0.26$). The
343 median difference in NYHA class on a good day between active and back-up pacing
344 was zero ($p > 0.99$). Median NYHA class on a bad day was 3 (IQRs 3 to 4) in pre
345 implant, 3 (IQRs 3 to 3) during active and 3 (IQRs 3 to 4) during back-up pacing
346 ($p = 0.013$). The median difference in NYHA class on a bad day between active and
347 back-up pacing was zero ($p = 0.42$). Subjects were also asked to report the ratio of
348 good to bad days throughout the week as: more good days than bad, more bad days

349 than good, or equal good and bad days. More good than bad days were reported
350 with active pacing, and more bad than good days were reported during backup
351 pacing (supplementary Figure S1).

352 **SF36 score:** Detailed SF36 results are in Supplementary Figure S2. The mean
353 General Health Score was 26 ± 18 pre-implant, 33 ± 30 during active pacing, and
354 25 ± 21 during back-up pacing ($p=0.18$). The mean increase in General Health Score
355 with active compared to back-up pacing was 3 (95% CIs -3 to 9, $p=0.42$) (Figure 3
356 panel C).

357 **KCCQ score:** The mean overall KCCQ score was 33 ± 22 pre-implant, 42 ± 22 during
358 active pacing, and 34 ± 16 during back-up pacing ($p=0.22$). The mean clinical KCCQ
359 score was 36 ± 18 pre-implant, 42 ± 22 during active pacing, and 36 ± 18 during back-up
360 pacing ($p=0.34$). The mean increase in overall KCCQ score with active compared to
361 back-up pacing was 7 ± 20 (95% CIs 19 to -5, $p=0.44$) (Figure 3 panel D). The mean
362 increase in clinical KCCQ score with active compared to back-up pacing was 6 ± 19
363 (95% CIs 18 to -5, $p=0.50$) (Figure 3 panel E).

364 **Doppler defined LVMCO gradient:** The mean Doppler defined gradient was 42 ± 32
365 mmHg pre-implant, 24 ± 17 mmHg during active pacing, and 46 ± 28 mmHg during
366 back-up pacing ($p=0.004$). The mean reduction in gradient with active compared to
367 back-up pacing was 21 ± 14 mmHg (95% CIs 11.5 to 29.9, $p=0.002$) (Figure 3 panel
368 F).

369 **6MWT:** The mean 6MWT distance was 296 ± 88 meters pre-implant, 329 ± 100 meters
370 during active pacing, and 286 ± 106 meters during back-up pacing ($p=0.038$). The
371 mean increase in 6MWT distance with active compared to back-up pacing was
372 43 ± 47 meters (95% CIs 71 to 14, $p=0.018$) (Figure 3 panel G).

373 **NT-proBNP:** The median NT-proBNP concentration was 483 (IQR 243 to 928)
374 ng/L/L pre-implant, 549 (IQR 286 to 1014) ng/L during active pacing, and 422 (IQR
375 301 to 818) ng/L during back-up pacing ($p=0.039$). The median increase in NT-
376 proBNP concentration during active compared to back-up pacing was 63 ng/L (IQR
377 136 ng/L, $p=0.12$) (Figure 3 panel H).

378 **VO₂ max:** The mean VO₂ max was 13.3 ± 2.4 mL/min/kg pre-implant, 14.4 ± 4.4
379 mL/min/kg during active pacing, and 12.4 ± 3.4 mL/min/kg during back-up pacing
380 ($p=0.24$). The mean increase in VO₂ max during active compared to back-up pacing
381 was 1.9 ± 4.4 mL/min/kg (95% CIs 1.0 to 4.9, $p=0.34$) (Figure 3 panel I).

382 **Safety**

383 **Hemodynamic pacing study and device implant:** 16 subjects underwent
384 successful device implantation, of whom 15 (94%) had uncomplicated procedures.
385 Cardiac vein perforation and subsequent pericardial effusion treated with
386 pericardiocentesis occurred in 1 case. In this subject the LV lead was not implanted,
387 and they received a dual chamber ICD without further complication. This subject was
388 withdrawn from the study after the implant procedure.

389 **Adverse events during follow-up:** There were two patient withdrawals during
390 follow-up due to adverse events unrelated to the study. One patient suffered an
391 acute myocardial infarction, and another went into persistent fast atrial fibrillation in
392 the first follow-up period.

393

394 4. Discussion

395 Patients with drug-refractory symptomatic LVMCO have very few therapeutic
396 options.^{9, 16} For the first time, we demonstrate that ventricular pacing tailored to
397 individual patient characteristics is safe, technically feasible, and improves LV
398 intracavity hemodynamics. Furthermore, we present data indicating improved patient
399 functional status, and provide the context and justification for a larger multicenter trial
400 powered for symptom and functional measures.

401 Other therapeutic options for symptomatic LVMCO include surgical myectomy,¹⁷
402 alcohol septal ablation (ASA),¹⁸ and cardiac transplant.¹⁹ The novel pharmacological
403 class of myosin inhibitors are not currently licensed for this indication. Prevalence of
404 LVMCO has been reported to be as high as 9-13% of HCM patients.^{20, 21} Notably, as
405 many patients with LVMCO have primary or secondary indications for transvenous
406 ICDs, a trial of PPOC therapy may have a key role earlier in the management of
407 these patients, with progression to other therapies if this fails.

408 **Surgical Myectomy:** Much of the published data on surgery for LVMCO comes from
409 a single center of surgical excellence.^{17, 22, 23} Results indicate similar levels of
410 absolute gradient reduction compared to PPOC. Symptoms were significantly
411 improved with myectomy in a cohort of patients with a less severe phenotype than
412 included in our trial (lower baseline functional limitation and prevalence of LVAA).¹⁷
413 Notably, high levels of early complications were reported,²³ and the surgical
414 expertise required for such specialist procedures is not widely available. By contrast,
415 most centers that implant devices for heart failure already have the experience,
416 expertise and resources required for PPOC. Additionally, as at least half of the
417 published surgical cohorts had pacemakers / ICDs prior to surgery,¹⁷ a trial of PPOC

418 can be considered before surgery. Finally, unlike for PPop, no randomized
419 prospective trials of myectomy have been completed.

420 **Alcohol septal ablation (ASA):** Data on the use of ASA in the treatment of LVMCO
421 is even more limited. ASA reduced obstructive gradients and improved symptoms in
422 a cohort 22 patients.¹⁸ However, severely elevated residual LVMCO gradients were
423 twice as common when compared to our PPop cohort (23% vs 12.5%). Furthermore,
424 ASA was associated with intra-procedural complete heart block in a third, and one
425 patient developed ventricular fibrillation.¹⁸ Once again, there have been no
426 prospective trials of ASA for this indication, and a trial of PPop prior to ASA may be
427 warranted in the context of baseline ICD indications and the high risk of ASA-related
428 conduction disease.²⁴

429 **Cardiac Myosin Inhibitors:** Recent trials of myosin inhibitors, a novel class of
430 agents, report reductions in LV outflow tract obstruction (LVOTO) gradients and
431 improved functional outcomes in patients with 'classic' obstructive HCM.²⁵ However,
432 perhaps as many as two thirds of HCM patients in EXPLORER-HCM did not achieve
433 primary outcomes, and patients with LVMCO were excluded from the trial. A trial of
434 myosin-inhibitors in symptomatic LVMCO patients is warranted; PPop may continue
435 to have a role in the management of patients refractory to that treatment, and in
436 those that have indications for transvenous ICDs.

437 **Future work**

438 Our trial provides the basis for a larger multicenter trial of PPop for refractory
439 LVMCO by providing positive signals of safety and clinical benefit, and data required
440 for a study powered to detect clinically meaningful improvements in symptoms and
441 functional status.

442 While technology developed for resynchronization pacing has enabled this study,
443 there is a need for equipment and techniques developed specifically for this
444 indication. Broadly, these will address challenges that include: predicting optimal
445 lead positioning prior to the invasive procedure; selective intubation of, and
446 attainment of lead stability in the cardiac vein of choice; mitigating effects of
447 myocardial fibrosis on pacing thresholds; and avoiding phrenic nerve capture. Most
448 notably, even small differences in pacing site location can result in strikingly different
449 hemodynamic effects (Figure 4); pre-implant techniques that predict where pacing is
450 likely to have greatest beneficial hemodynamic effects, and an ability to pace beyond
451 anatomical restrictions imposed by cardiac venous anatomy will be key
452 developments.

453 **Limitations**

454 This study was not powered to detect functional or symptomatic benefit and included
455 only the most severely symptomatic patients. Despite this, we demonstrate
456 significant improvements in the 6-minute walking test, and the overwhelming majority
457 of other functional parameters indicate trends for symptom benefit. Further, to avoid
458 exposing participants to the risks of repeat invasive procedure during follow-up, we
459 relied on Doppler echocardiography to report relative changes in LVMCO gradient,
460 with known shortcomings in this population.⁴ Nonetheless, the significantly lower
461 Doppler-derived gradients during active pacing indicate that the beneficial
462 hemodynamic effect is sustained. Although not significant, mean NT-proBNP was
463 greater following pacing, and was the only secondary outcome not to show a trend
464 towards benefit. Altered atrio-ventricular coupling and/or contractile desynchrony
465 may affect the production of NT-proBNP independently to the magnitude of mid-
466 cavity obstruction; further investigation is warranted.

467 **5. Conclusions**

468 In the first randomized placebo-controlled trial of therapy for symptomatic mid-cavity
469 obstructive HCM, we demonstrate that PPop is a safe and effective therapeutic
470 option. Personalized approaches to pacing most commonly identifies pacing from a
471 site in the LV as the most effective place from which to obtain gradient reduction.
472 Future work will include trials designed to detect symptom and physical performance
473 benefit and attempt to determine how pacing contributes to LVMCO management
474 algorithms that include myosin inhibitors and other invasive therapeutic options.

475

476

477 **Acknowledgments**

478 The authors would like to acknowledge the contributions of the Data Safety
479 Monitoring and Trial Steering Committees, especially the patient representatives, for
480 their expertise and time.

481 This study was supported by the Barts Cardiovascular Clinical Trials Unit (CVCTU),
482 a branch of the Barts CTU UKCRC Reg No. 4. The authors would particularly like to
483 acknowledge the work of Anna Bellin, Jackie Cooper, Jane Field, Thomas Godec,
484 and Dilveer Singh Sually for their time and support in the design and running of this
485 trial.

486 **Sources of Funding**

487 J.W. Malcolmson is funded by a National Institute for Health and Care Research
488 Clinical Doctoral Research Fellowship (ICACDRF-2016-02-068). R.K. Hughes is
489 supported by the British Heart Foundation (grant number FS/17/82/33222). This
490 work acknowledges the support of the National Institute for Health and Care
491 Research Barts Biomedical Research Centre (NIHR203330); a delivery partnership
492 of Barts Health NHS Trust, Queen Mary University of London, St George's University
493 Hospitals NHS Foundation Trust and St George's University of London.

494 **Disclosures**

495 SEP provides Consultancy to Circle Cardiovascular Imaging Inc., Calgary, Alberta,
496 Canada.

497 LL has received speaker fees from Sanofi, Alnylam and Bristol Myers Squibb (BMS);
498 and received a grant from BMS.

499

500 **References:**

- 501 1. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al.
502 Classification of the cardiomyopathies: A position statement from the
503 european society of cardiology working group on myocardial and pericardial
504 diseases. *Eur Heart J*. 2008;29:270-276
- 505 2. Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in
506 hypertrophic cardiomyopathy: Past, present and future. *Heart*. 2008;94:1276-
507 1281
- 508 3. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R, et al. Left
509 ventricular outflow tract obstruction and sudden death risk in patients with
510 hypertrophic cardiomyopathy. *Eur Heart J*. 2006;27:1933-1941
- 511 4. Malcolmson JW, Hamshere SM, Joshi A, O'Mahony C, Dhinoja M, Petersen
512 SE, et al. Doppler echocardiography underestimates the prevalence and
513 magnitude of mid-cavity obstruction in patients with symptomatic hypertrophic
514 cardiomyopathy. *Catheter Cardiovasc Interv*. 2018;91:783-789
- 515 5. Hughes RK, Knott KD, Malcolmson J, Augusto JB, Mohiddin SA, Kellman P,
516 et al. Apical hypertrophic cardiomyopathy: The variant less known. *J Am*
517 *Heart Assoc*. 2020;9:e015294
- 518 6. Sherrid MV, Bernard S, Tripathi N, Patel Y, Modi V, Axel L, et al. Apical
519 aneurysms and mid-left ventricular obstruction in hypertrophic
520 cardiomyopathy. *JACC Cardiovasc Imaging*. 2023
- 521 7. Yang K, Song YY, Chen XY, Wang JX, Li L, Yin G, et al. Apical hypertrophic
522 cardiomyopathy with left ventricular apical aneurysm: Prevalence, cardiac
523 magnetic resonance characteristics, and prognosis. *Eur Heart J Cardiovasc*
524 *Imaging*. 2020;21:1341-1350

- 525 8. Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al.
526 Clinical implications of midventricular obstruction in patients with hypertrophic
527 cardiomyopathy. *J Am Coll Cardiol*. 2011;57:2346-2355
- 528 9. Shah A, Duncan K, Winson G, Chaudhry FA, Sherrid MV. Severe symptoms
529 in mid and apical hypertrophic cardiomyopathy. *Echocardiography*.
530 2009;26:922-933
- 531 10. Begley D, Mohiddin S, Fananapazir L. Dual chamber pacemaker therapy for
532 mid-cavity obstructive hypertrophic cardiomyopathy. *Pacing Clin*
533 *Electrophysiol*. 2001;24:1639-1644
- 534 11. Po JR, Kim B, Aslam F, Arabadjian M, Winson G, Cantales D, et al. Doppler
535 systolic signal void in hypertrophic cardiomyopathy: Apical aneurysm and
536 severe obstruction without elevated intraventricular velocities. *J Am Soc*
537 *Echocardiogr*. 2015;28:1462-1473
- 538 12. Nakamura T, Matsubara K, Furukawa K, Azuma A, Sugihara H, Katsume H,
539 et al. Diastolic paradoxical jet flow in patients with hypertrophic cardiomyopathy:
540 Evidence of concealed apical asynergy with cavity obliteration. *J Am Coll*
541 *Cardiol*. 1992;19:516-524
- 542 13. Malcolmson JW, Hughes RK, Joshi A, Cooper J, Breitenstein A, Ginks M, et
543 al. Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive
544 hypertrophic cardiomyopathy. *Ther Adv Cardiovasc Dis*.
545 2022;16:17539447221108816
- 546 14. Sorajja P, Ommen SR, Nishimura RA. Symptomatic obstructive hypertrophic
547 cardiomyopathy. *Circ Cardiovasc Interv*. 2013;6:586-591

- 548 15. Elesber A, Nishimura RA, Rihal CS, Ommen SR, Schaff HV, Holmes DR, Jr.
549 Utility of isoproterenol to provoke outflow tract gradients in patients with
550 hypertrophic cardiomyopathy. *Am J Cardiol.* 2008;101:516-520
- 551 16. Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M,
552 Cecchi F, et al. 2014 esc guidelines on diagnosis and management of
553 hypertrophic cardiomyopathy: The task force for the diagnosis and
554 management of hypertrophic cardiomyopathy of the european society of
555 cardiology (esc). *Eur Heart J.* 2014;35:2733-2779
- 556 17. Sun D, Schaff HV, Nishimura RA, Geske JB, Dearani JA, Ommen SR.
557 Transapical septal myectomy for hypertrophic cardiomyopathy with
558 midventricular obstruction. *Ann Thorac Surg.* 2021;111:836-844
- 559 18. Yang YJ, Fan CM, Yuan JQ, Wang SY, Song YH, Qiao SB, et al.
560 Effectiveness of alcohol septal ablation versus transaortic extended
561 myectomy in hypertrophic cardiomyopathy with midventricular obstruction. *J*
562 *Interv Cardiol.* 2016;29:619-627
- 563 19. Seferovic PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, et al.
564 Heart failure in cardiomyopathies: A position paper from the heart failure
565 association of the european society of cardiology. *Eur J Heart Fail.*
566 2019;21:553-576
- 567 20. Minami Y, Haruki S, Hagiwara N. Phenotypic overlap in hypertrophic
568 cardiomyopathy: Apical hypertrophy, midventricular obstruction, and apical
569 aneurysm. *J Cardiol.* 2014;64:463-469
- 570 21. Nie C, Zhu C, Xiao M, Yang Q, Meng Y, Wu R, et al. Mid-ventricular
571 obstruction is associated with non-sustained ventricular tachycardia in

- 572 patients with hypertrophic obstructive cardiomyopathy. *Clin Cardiol.*
573 2021;44:555-562
- 574 22. Said SM, Schaff HV, Abel MD, Dearani JA. Transapical approach for apical
575 myectomy and relief of midventricular obstruction in hypertrophic
576 cardiomyopathy. *J Card Surg.* 2012;27:443-448
- 577 23. Kunkala MR, Schaff HV, Nishimura RA, Abel MD, Sorajja P, Dearani JA, et al.
578 Transapical approach to myectomy for midventricular obstruction in
579 hypertrophic cardiomyopathy. *Ann Thorac Surg.* 2013;96:564-570
- 580 24. Veselka J, Liebrechts M, Cooper R, Faber L, Januska J, Kashtanov M, et al.
581 Outcomes of patients with hypertrophic obstructive cardiomyopathy and
582 pacemaker implanted after alcohol septal ablation. *JACC Cardiovasc Interv.*
583 2022;15:1910-1917
- 584 25. Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P,
585 et al. Mavacamten for treatment of symptomatic obstructive hypertrophic
586 cardiomyopathy (explorer-hcm): A randomised, double-blind, placebo-
587 controlled, phase 3 trial. *Lancet.* 2020;396:759-769
- 588
589

590 Tables

591 Table 1: Inclusion and exclusion criteria

Inclusion Criteria

- a) Male or female, >18 years.
- b) Referred for PPM +/- ICD implantation for either primary prevention of sudden cardiac death or other indications such as heart block or obstructive physiology.
- c) HCM patients with evidence of mid-cavity gradient demonstrated by echocardiography and gradient ≥ 30 mmHg confirmed by cardiac catheterization at rest or with isoprenaline provocation.
- d) All patients should be taking maximum tolerated doses of beta blockers or verapamil with or without disopyramide.
- e) Symptoms refractory to optimum medical therapy as above, for example breathlessness, chest pain, dizziness, or syncope.

Exclusion Criteria

- a) Patients with multi-level obstruction, i.e. across the mid-cavity and outflow tract.
- b) Patients with moderate or severe valvular stenosis or regurgitation due to primary valvular disease.
- c) Patients with untreated symptomatic coronary disease.
- d) Patients in atrial fibrillation at the time of implantation.
- e) Pregnancy.
- f) Renal failure with eGFR <20mL/min.
- g) Any patient not suitable in the clinician's opinion.
- h) Any patient who is for whatever reason is not expected to survive for

more than one year.

i) Patients unable to provide informed consent.

592


593 **Table 2: Baseline characteristics**

Demographics and symptoms	n=17
Age at recruitment (years)	55.9 ± 10.3
Male, n (%)	9 (53)
Family history inherited heart disease, n (%)	10 (59)
HTN, n (%)	11 (65)
Chest pain, n (%)	15 (88)
Dyspnea, n (%)	17 (100)
Palpitations, n (%)	16 (94)
Presyncope, n (%)	14 (82)
SCD risk profile	n=17
Family history of SCD, n (%)	1 (6)
Unexplained syncope, n (%)	7 (41)
Prior NSVT on Holter / ICD (out of 16), n (%)	09/16 (56)
Maximum LV wall thickness ≥30 mm, n (%)	0 (0)
LVAA, n (%)	14 (82)
LVOTO gradient ≥30 mmHg, n (%)	0 (0)
ESC SCD risk score (% 5-year mortality)	3.7 ± 2.1
≥ intermediate risk score, n (%)	6 (35)
SCD risk factors (0/1/2/3 risk factors), n (%)	2 (12) / 9 (53) / 5 (29) / 1 (6)
Medications	n=17
β-Blockers, n (%)	9 (53)
Calcium channel blockers, n (%)	13 (76)
Disopyramide, n (%)	6 (35)

Anticoagulation, n (%)	7 (41)
Number on 1/2/3 medical therapies, n (%)	9 (53) / 7 (41) / 1 (6)
Echocardiography	n=17
Max LVWT (mm)	20 ± 4
Resting Doppler LVMCO gradient (mmHg)	32 ± 21
Post exercise Doppler LVMCO gradient (mmHg)	50 ± 35
LA diameter (mm)	40 ± 5
LVAA, n (%)	14 (82)
Paradoxical apical diastolic flow, n (%)	13 (76)
CMR	n=12
LVEF (%)	69 ± 9
Max LVWT (mm)	20 ± 3
LV mass (g)	167 ± 37
LVAA, n (%)	9 (75)
Presence of LGE, n (%)	12 (100)
Apical LGE, n (%)	12 (100)
Circumferential perfusion defect (out of 9), n (%)	8/9 (89)
Apical thrombus, n (%)	0 (0)

Data are represented as mean ± SD or n (%). HTN, hypertension; SCD, Sudden Cardiac Death Risk; NSVT, non-sustained ventricular tachycardia; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVAA, left ventricular apical aneurysm; LVOTO, left ventricular outflow tract obstruction; ESC, European Society of Cardiology; LVWT, LV wall thickness; LVMCO, left ventricular mid-cavity obstruction; LA, left atrial; CMR, cardiac magnetic resonance; LVEF, left ventricular ejection fraction; LGE, late gadolinium enhancement.


595 **Figures with Figure Legends**



596

597 **Figure 1:** Trial consort diagram. (n, number; MI, myocardial infarction; AF, atrial

598 fibrillation)



599

600 **Figure 2:** Acute change in LVMCO gradient. Sinus, sinus rhythm; Paced, optimal
601 pacing setting. Error bars: mean \pm SD. ****= $p < 0.0001$ in pairwise comparisons.

602

603

604

605

606

607

608

609

610

611

612


613

614

615

616

617



618

619 **Figure 3:** Secondary outcome data across 3 time points: pre-implant, active pacing,

620 and back-up pacing (A-I) (order of active and back-up pacing was randomized).


621 NYHA class on a good and bad day (A & B); SF36 General Health Score (C), KCCQ

622 overall and clinical scores (D & E); Doppler LVMCO gradient (F); 6MWT distance

623 (G); NT-BNP level (H); and VO2 max (I). Error bars: mean ± SD. Results of multiple

624 comparisons: ns= p > 0.05, *=p < 0.05, **=p < 0.01 in multiple comparisons.

625



626

627 **Figure 4:** Example pressure traces from hemodynamic pacing study, with overlaid

628 fluoroscopy of the LV quadripolar lead in two different cardiac veins. Pacing from the

629 more lateral position in the PLV produced an unsatisfactory reduction in LVMCO

630 gradient, whereas pacing from the MCV almost entirely abolished the obstructive

631 gradient. A schematic representation of pacing leads and catheter orientation relative

632 to ventricular chambers can be seen at the bottom of the figure. ICD, implantable

633 cardioverter defibrillator; LV, left ventricular; LVAA, left ventricular apical aneurysm;

634 LV2, quadripolar lead pole 2; MCV, middle cardiac vein; PLV, posterolateral vein;

635 RA, right atrial; RVp, right ventricular pacing.